Today's Low
₹ 827.40
Today's High
₹ 863.65
52 Weeks Low
₹ 264.35
52 Weeks High
₹ 392.00
Lower
₹ 675.90
Upper
₹ 1,013.80
Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australasia, North America, Europe, Asia, India, and internationally. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and oral liquids, as well as semi powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women's health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Clavicin, Combiart, Solcer, Melonax, Duotab, and Vitafer brands; and drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for institutional business. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. Strides Pharma Science Limited was incorporated in 1990 and is headquartered in Bengaluru, India.
No Data Found
No of shares Outstanding
EPS-TTM
Face Value
Book Value
Net Asset Value
ROE
ROA
ROCE
Dividend Yield
Total Debt
Sales Growth
PAT Growth
Particulars | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2012 | FY 2011 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 3,135.3 | 3,361.8 | 2,817.2 | 2,370.6 | 3,048.7 | 2,446.5 | 3,791.8 | 3,514.9 | 1,429.5 | 1,308.6 | 1,410.9 | 1,625.3 |
Total Non-Current Assets | 3,130.0 | 3,398.9 | 3,999.6 | 3,581.1 | 4,758.1 | 4,101.3 | 4,243.1 | 3,845.2 | 1,039.9 | 787.7 | 3,383.9 | 3,711.3 |
Total Assets | 6,373.4 | 6,760.7 | 6,816.8 | 5,953.2 | 7,806.8 | 6,584.9 | 8,034.9 | 7,360.1 | 2,469.4 | 2,096.3 | 4,796.0 | 5,342.2 |
Total Current Liabilities | 2,990.2 | 3,411.7 | 2,738.4 | 2,544.9 | 2,662.2 | 1,899.3 | 3,103.9 | 1,892.0 | 1,019.9 | 707.4 | 1,797.3 | 2,791.7 |
Total Non-Current Liabilities | 1,210.3 | 965.7 | 1,264.5 | 813.7 | 2,342.9 | 2,067.3 | 2,048.7 | 2,760.0 | 285.8 | 306.4 | 900.6 | 1,132.6 |
Shareholder's Funds | 2,212.3 | 2,359.2 | 2,776.7 | 2,527.4 | 2,648.7 | 2,463.7 | 2,748.8 | 2,657.9 | 1,144.9 | 1,006.8 | 2,026.2 | 1,371.5 |
Total Liabilities | 6,373.4 | 6,760.7 | 6,816.8 | 5,953.2 | 7,806.8 | 6,584.9 | 8,034.9 | 7,360.1 | 2,469.4 | 2,096.3 | 4,796.0 | 5,342.2 |
The Industry Debt to Equity Ratio stands at 0.22, vs the Debt to Equity Ratio of 0.78, which results in a Negative aspect.
The Industry Quick Ratio stands at 1.60, vs the Quick Ratio of 0.62, which results in a Negative aspect.
The Industry Price to BV stands at 6.08, vs the Price to BV of 3.57, which results in a Negative aspect.
The Industry Current Ratio stands at 2.31, vs the Current Ratio of 0.93, which results in a Negative aspect.
Particulars | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2012 | FY 2011 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Income | 3,688.4 | 3,070.3 | 3,315.9 | 2,752.0 | 2,178.4 | 2,845.1 | 2,755.4 | 2,862.2 | 1,195.9 | 1,341.0 | 961.8 | 2,550.0 |
Total Expenditure | 3,303.1 | 3,091.8 | 2,689.1 | 2,236.1 | 1,936.1 | 2,430.8 | 2,228.1 | 2,448.2 | 967.0 | 1,117.5 | 861.2 | 2,059.4 |
Operating Profit(Excl OI) | 520.5 | 111.9 | 686.3 | 569.0 | 283.2 | 490.6 | 688.4 | 506.1 | 267.4 | 283.7 | 134.8 | 522.4 |
Add: Other Income | 135.2 | 133.4 | 59.4 | 53.1 | 40.8 | 76.3 | 161.1 | 92.1 | 38.6 | 60.2 | 34.2 | 31.7 |
Operating Profit | 520.5 | 111.9 | 686.3 | 569.0 | 283.2 | 490.6 | 688.4 | 506.1 | 267.4 | 283.7 | 134.8 | 522.4 |
Less: Interest | 261.1 | 176.7 | 150.1 | 155.7 | 79.3 | 196.2 | 183.1 | 168.2 | 47.4 | 108.9 | 79.5 | 194.8 |
PBDT | 259.4 | -64.9 | 536.2 | 413.3 | 203.9 | 294.4 | 505.3 | 337.9 | 220.0 | 174.8 | 55.3 | 327.5 |
Less: Depreciation Amortization | 243.3 | 233.0 | 206.3 | 173.7 | 117.4 | 154.0 | 126.2 | 131.3 | 64.0 | 56.5 | 30.9 | 104.3 |
PBT & Exceptional Items | 16.1 | -297.9 | 329.9 | 239.6 | 86.5 | 140.3 | 379.2 | 206.7 | 156.0 | 118.3 | 24.5 | 223.2 |
Less: Exceptional Income Expenses | -17.0 | -243.8 | 43.4 | -77.7 | 21.6 | -43.6 | -36.4 | -41.4 | -7.4 | -26.6 | 700.1 | 49.5 |
Profit Before Tax | -286.2 | -652.5 | 275.4 | 54.7 | 62.4 | 80.0 | 343.1 | 160.6 | 148.6 | 91.8 | 724.6 | 272.7 |
Less: Taxation | -55.3 | -178.3 | 31.7 | 11.3 | -26.9 | 5.7 | 63.4 | 42.5 | 147.6 | 324.5 | 11.2 | 38.7 |
Profit After Tax | -230.9 | -474.3 | 243.8 | 43.4 | 89.3 | 74.3 | 279.7 | 118.2 | 1.0 | -232.8 | 713.4 | 234.0 |
Earnings Per Share | -2.2 | -5.1 | 3.0 | 0.4 | 3.6 | 7.4 | 4.5 | 1.2 | 14.2 | 29.7 | 12.1 | 3.9 |
The Industry Dividend Yield stands at 0.59, vs the Dividend Yield of 0.18, which results in a Negative aspect.
The Industry PAT Growth stands at 32.10, vs the PAT Growth of -51.42, which results in a Negative aspect.
The Industry PAT Margin stands at 9.73, vs the PAT Margin of 0.92, which results in a Negative aspect.
The Industry PE Ratio stands at 43.11, vs the PE Ratio of 0.00, which results in a Negative aspect.
Particulars | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2012 | FY 2011 | FY 2010 | FY 2009 | FY 2008 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Profit Before Tax | -267.6 | -652.5 | 289.4 | 48.5 | 344.4 | 705.8 | 497.1 | 146.4 | 992.0 | 2,889.9 | 949.5 | 272.7 | 186.4 | 142.9 | 114.9 |
Tax Paid | 87.6 | 2.3 | 156.8 | -45.0 | -55.8 | -53.6 | -58.6 | -77.0 | -56.0 | -125.9 | -88.7 | -58.3 | -39.3 | -13.7 | -9.8 |
Adjustment | 682.2 | 582.3 | 363.3 | 527.5 | 94.6 | -274.5 | 190.9 | 345.6 | -756.7 | -2,775.0 | -415.9 | 113.8 | 178.9 | 42.8 | 19.5 |
Changes In Working Capital | -267.6 | -652.5 | 289.4 | 48.5 | 344.4 | 705.8 | 497.1 | 146.4 | 992.0 | 2,889.9 | 949.5 | 272.7 | 186.4 | 142.9 | 114.9 |
Cash Flow after changes in Working Capital | -43.2 | -260.1 | 324.6 | 249.8 | 115.8 | 240.6 | 346.8 | 150.3 | 139.4 | -145.8 | 223.0 | 515.4 | 363.2 | 103.3 | 127.5 |
Cash Flow from Operating Activities | 44.4 | -257.8 | 481.4 | 204.8 | 60.1 | 187.1 | 288.1 | 73.2 | 83.4 | -271.7 | 134.3 | 457.1 | 323.9 | 89.6 | 117.7 |
Cash Flow from Investing Activities | 302.5 | -118.7 | -520.8 | 1,306.2 | -148.5 | 582.6 | -686.7 | -2,224.8 | 51.9 | 4,077.1 | 806.5 | -656.5 | -941.0 | -147.6 | -218.9 |
Cash Flow from Financing Activities | -213.9 | 421.3 | -15.8 | -1,709.4 | 194.3 | -1,015.7 | 338.2 | 2,943.9 | -421.3 | -3,318.5 | -990.0 | 89.4 | 850.1 | 91.6 | 13.4 |
Net Cash Inflow / Outflow | 133.0 | 44.8 | -55.2 | -198.5 | 105.8 | -246.0 | -60.3 | 792.4 | -286.0 | 486.9 | -49.2 | -110.0 | 233.0 | 33.6 | -87.7 |
Opening Cash & Cash Equivalents | 170.7 | 125.8 | 182.2 | 365.9 | 256.2 | 515.1 | 1,110.7 | 298.9 | 586.0 | 132.0 | 211.9 | 325.2 | 79.0 | 45.9 | 179.3 |
Closing Cash & Cash Equivalent | 303.5 | 170.7 | 125.8 | 182.2 | 365.9 | 256.2 | 515.1 | 1,110.7 | 298.4 | 586.0 | 132.0 | 212.3 | 325.2 | 78.8 | 45.9 |
The Industry PFCF Ratio stands at 25.12, vs the PFCF Ratio of -11.79, which results in a Negative aspect.
The Industry PCF RATIO stands at 24.27, vs the PCF RATIO of 14.11, which results in a Negative aspect.
Particulars | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 | Jun 2020 | Mar 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Sales | 10,376.7 | 9,994.3 | 9,299.9 | 9,863.7 | 8,648.5 | 8,971.0 | 9,400.7 | 8,660.2 | 7,943.9 | 7,214.7 | 6,883.7 | 9,084.9 | 8,320.2 | 7,935.6 | 7,818.0 | 6,186.4 |
Total Income | 10,464.2 | 10,352.8 | 9,386.4 | 10,134.9 | 8,910.5 | 9,345.2 | 9,625.9 | 9,520.8 | 8,045.8 | 7,436.8 | 7,070.2 | 9,215.4 | 8,464.2 | 8,113.1 | 7,980.0 | 6,362.9 |
Total Expenditure | 8,438.6 | 8,463.0 | 7,634.0 | 8,308.1 | 7,485.0 | 8,129.3 | 8,888.8 | 8,238.5 | 7,928.6 | 7,350.4 | 7,437.2 | 7,512.6 | 6,726.2 | 6,363.5 | 6,307.9 | 5,536.0 |
PBIDT (Excl OI) | 1,938.1 | 1,531.3 | 1,665.9 | 1,555.6 | 1,163.4 | 841.7 | 511.9 | 421.6 | 15.3 | -135.7 | -553.5 | 1,572.4 | 1,594.1 | 1,572.1 | 1,510.1 | 650.4 |
Other Income | 87.5 | 358.5 | 86.5 | 271.2 | 262.0 | 374.2 | 225.1 | 860.6 | 101.9 | 222.1 | 186.5 | 130.5 | 144.0 | 177.5 | 162.0 | 176.5 |
Operating Profit | 2,025.7 | 1,889.8 | 1,752.4 | 1,826.8 | 1,425.4 | 1,215.9 | 737.0 | 1,282.2 | 117.2 | 86.4 | -367.0 | 1,702.8 | 1,738.0 | 1,749.6 | 1,672.1 | 826.9 |
Interest | 792.8 | 785.9 | 764.2 | 805.2 | 584.4 | 676.4 | 545.4 | 494.8 | 422.5 | 435.6 | 414.5 | 416.1 | 346.8 | 368.7 | 369.1 | 403.3 |
Exceptional Items | -100.7 | -1,649.3 | -59.8 | -73.4 | 415.6 | 145.2 | -657.7 | -769.5 | -154.3 | -599.0 | -915.4 | -9.3 | -137.7 | 131.3 | 449.2 | -1,701.0 |
PBDT | 1,132.1 | -545.4 | 928.4 | 948.2 | 1,256.6 | 684.7 | -466.1 | 17.9 | -459.7 | -948.1 | -1,697.0 | 1,277.4 | 1,253.6 | 1,512.3 | 1,752.2 | -1,277.4 |
Depreciation | 512.3 | 601.1 | 595.9 | 609.3 | 602.2 | 617.0 | 604.0 | 606.8 | 609.0 | 565.6 | 548.8 | 518.6 | 525.1 | 527.9 | 491.3 | 453.4 |
Profit Before Tax | 619.9 | -1,146.4 | 332.5 | 338.9 | 654.4 | 67.7 | -1,070.1 | -588.8 | -1,068.6 | -1,513.7 | -2,245.8 | 758.9 | 728.5 | 984.4 | 1,260.9 | -1,730.8 |
Tax | 101.0 | -74.4 | 96.8 | 70.9 | 40.9 | -384.0 | -280.7 | -1,314.8 | -44.8 | -67.6 | -355.4 | 114.9 | 107.7 | 61.0 | 32.8 | -104.7 |
Provisions and contingencies | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Profit After Tax | 518.8 | -1,072.0 | 235.7 | 268.1 | 613.5 | 451.7 | -789.4 | 726.0 | -1,023.8 | -1,446.1 | -1,890.4 | 644.0 | 620.7 | 923.4 | 1,228.0 | -1,626.1 |
Net Profit | 1,060.3 | -1,072.0 | 235.7 | 268.1 | 613.5 | 637.4 | -789.4 | 726.0 | -1,023.8 | -1,446.1 | -1,890.4 | 635.7 | 620.7 | 1,071.1 | 1,228.0 | -1,617.9 |
ADDITIONAL INFOS: | ||||||||||||||||
Equity Capital | 918.9 | 903.3 | 903.0 | 903.0 | 903.0 | 902.9 | 898.0 | 897.9 | 897.9 | 897.8 | 897.2 | 896.8 | 896.4 | 896.3 | 895.7 | 895.5 |
Reserves | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
EPS | -0.5 | -14.5 | -0.8 | -1.1 | -8.9 | 0.5 | -15.1 | 3.3 | -13.6 | -18.1 | -22.9 | 5.2 | 4.2 | 7.4 | 11.6 | -22.9 |
Operating Profit Margin | 19.5 | 18.9 | 18.8 | 18.5 | 16.5 | 13.6 | 7.8 | 14.8 | 1.5 | 1.2 | -5.3 | 18.7 | 20.9 | 22.0 | 21.4 | 13.4 |
Net Profit Margin | 5.0 | -10.7 | 2.5 | 2.7 | 7.1 | 5.0 | -8.4 | 8.4 | -12.9 | -20.0 | -27.5 | 7.1 | 7.5 | 11.6 | 15.7 | -26.3 |
The Industry Net Sales Growth stands at 11.07, vs the Net Sales Growth of 26.33, which results in a Positive aspect.
The Industry Mcap Growth stands at 19.65, vs the Mcap Growth of -31.60, which results in a Negative aspect.
Type | Classic | Woodie | Camarilla |
---|---|---|---|
R4 | 884.85 | 905.93 | 855.85 |
R3 | 875.57 | 874.85 | 850.35 |
R2 | 866.28 | 865.93 | 848.52 |
R1 | 855.57 | 854.85 | 846.68 |
Pivot | 846.28 | 845.93 | 846.28 |
S1 | 835.57 | 834.85 | 843.02 |
S2 | 826.28 | 825.93 | 841.18 |
S3 | 815.57 | 814.85 | 839.35 |
S4 | 804.85 | 785.93 | 833.85 |
(All Values are in INR)
1 Day
1 Week
1 Month
Stoch RSI
91.95
Bearish
RSI
64.90
Neutral
ROC
8.40
Bullish
UltimateOscillator
47.99
Neutral
Williams Indicator
-14.05
Bearish
CCI Indicator
75.54
Neutral
MACD
-2,332.66
Bearish
Stochastic Indicator
81.04
Neutral
ATR
27.41
Low Volatility
Ex-Date | Ratio | Record Date |
---|
Ex-Date | Ratio | Record Date |
---|---|---|
Announcement Date | Dividend Amount | Dividend Percentage of FV | Dividend Type |
---|---|---|---|
04-08-2023 | 1.50 | 15 | Final |
05-08-2021 | 2.50 | 25 | Final |
Date Of Conduct | Board Meeting Details |
---|---|
30-01-2024 | Quarterly Results |
30-10-2023 | Quarterly Results |
25-09-2023 | Scheme of Arrangement |
02-08-2023 | Quarterly Results |
25-05-2023 | Final Dividend & Audited Results |
24-01-2023 | Quarterly Results |
14-11-2022 | Quarterly Results |
29-07-2022 | Quarterly Results |
25-07-2022 | Inter alia, to consider and approve Intimation of raising of funds by way of issuance of Non-Convertible Debentures under Regulation 29 of SEBI Listing Regulations. |
24-05-2022 | Quarterly Results & Dividend & Audited Results |
10-02-2022 | Quarterly Results (Revised) |
28-01-2022 | Quarterly Results |
10-11-2021 | Quarterly Results |
06-08-2021 | Quarterly Results |
27-05-2021 | Audited Results |